BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24978917)

  • 1. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.
    Shang Y; Chai N; Gu Y; Ding L; Yang Y; Zhou J; Ren G; Hao X; Fan D; Wu K; Nie Y
    Arch Pathol Lab Med; 2014 Jul; 138(7):910-9. PubMed ID: 24978917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
    Ravindranath NM; Shuler C
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
    Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
    J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.
    Christmas SE; de la Mata Espinosa CT; Halliday D; Buxton CA; Cummerson JA; Johnson PM
    Immunology; 2006 Dec; 119(4):522-8. PubMed ID: 16999828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.
    Simpson KL; Jones A; Norman S; Holmes CH
    Am J Pathol; 1997 Nov; 151(5):1455-67. PubMed ID: 9358772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD55 and CD59 protein expression by Apodemus (field mice) sperm in the absence of CD46.
    Clift LE; Dvorakova-Hortova K; Frolikova M; Andrlikova P; Salman S; Stopka P; Flanagan BF; Johnson PM
    J Reprod Immunol; 2009 Jul; 81(1):62-73. PubMed ID: 19501411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and modulation of RPE cell membrane complement regulatory proteins.
    Yang P; Tyrrell J; Han I; Jaffe GJ
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3473-81. PubMed ID: 19168900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.
    Wu Y; Wang Y; Qin F; Wang Z; Wang Y; Yang Y; Zheng H; Wang Y
    Am J Physiol Gastrointest Liver Physiol; 2014 Jun; 306(12):G1056-64. PubMed ID: 24763553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complement regulatory proteins CD55 (decay accelerating factor) and CD59 are expressed on the inner acrosomal membrane of human spermatozoa as well as CD46 (membrane cofactor protein).
    Cummerson JA; Flanagan BF; Spiller DG; Johnson PM
    Immunology; 2006 Jul; 118(3):333-42. PubMed ID: 16827894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.
    Rushmere NK; Knowlden JM; Gee JM; Harper ME; Robertson JF; Morgan BP; Nicholson RI
    Int J Cancer; 2004 Mar; 108(6):930-6. PubMed ID: 14712499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59.
    Leaderer D; Cashman SM; Kumar-Singh R
    J Gene Med; 2015; 17(6-7):101-15. PubMed ID: 25917932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.
    Nuutila J; Jalava-Karvinen P; Hohenthal U; Kotilainen P; Pelliniemi TT; Nikoskelainen J; Lilius EM
    Hum Immunol; 2013 May; 74(5):522-30. PubMed ID: 23376460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration.
    Singh A; Faber C; Falk M; Nissen MH; Hviid TV; Sørensen TL
    Am J Ophthalmol; 2012 Jul; 154(1):193-199.e2. PubMed ID: 22541656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research progression on complement regulatory proteins CD46, CD55, and CD59 in tumor immunotherapy].
    Qin C; Cai XY
    Ai Zheng; 2006 Nov; 25(11):1450-3. PubMed ID: 17094920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
    Ziller F; Macor P; Bulla R; Sblattero D; Marzari R; Tedesco F
    Eur J Immunol; 2005 Jul; 35(7):2175-83. PubMed ID: 15971270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.